Searched for
BIOPHARMA SECTOR GROWTH
Karnataka plans $400 billion Bengaluru region economy by 2037Karnataka plans to expand Bengaluru's economy to $400 billion by 2037. The master plan aims to create millions of new jobs and boost key se...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Karnataka's bioeconomy reaches $39 billion in 2025: ReportThe Karnataka Bioeconomy Report 2025, released by the state's IT/BT ministry, in collaboration with the Association of Biotechnology Led En...
- Budget 2026 bets on biopharma, SME capital to drive resilient growth: Industry leadersThe Union Budget 2026-27 focuses on fortifying the Indian economy against global volatility through strategic investments in technology, he...
- Budget 2026: Job creation and skill development top the agendaIn an era of economic transformation, the Union Budget puts a spotlight on job creation and skill enhancement, laying the groundwork for a ...
- Budget to boost economy, enhance India's global competitiveness: India IncIndia Inc has welcomed the Union Budget 2026-27. Industry leaders believe it is a budget for the real economy. It focuses on enhancing Indi...
- Biopharma Shakti programme key enabler for India's journey towards value leadership: Dr Reddy''s LabWith its 2026 Union Budget, India places a spotlight on the future of healthcare, specifically targeting biologics and biosimilars. A visio...
- Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturingUnion Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...
- Budget 2026: Sitharaman’s six-point plan to propel India’s next growth phaseUnion Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- Syngene's CEO Jonathan Hunt says India now offers intellectual arbitrage to firms“A young scientist joining a company like Syngene can travel the world scientifically without ever having to leave Bengaluru. It provides o...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- Our Malaysia facility is focussed on insulin & insulin analogues: Kiran Mazumdar Shaw, BioconIt is likely to take some time before we can actually start very aggressively marketing globally from the Malaysia facility.
- Policy, infrastructure main hurdles in Indian pharma R&D: ReportThe McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...
- India can become innovation hub for bio-pharma: BCG reportEmerging markets will drive 70% of growth in the pharma industry and India will require supportive policies to leverage the BioPharma.
- Revenues of Indian biotech sector surge to $4 bn in 2010-11The biotech industry, without the life sciences education component, recorded revenue growth of 21.5 per cent vis-a-vis 2009-10 revenues of...
- Indian healthcare market to grow despite slowdown: McKinseyNotwithstanding the current global economic crisis, India's pharmaceutical industry and its health care market are expected to grow rapidly...
Load More
